Virologic failure with a raltegravir-containing antiretroviral regimen and concomitant calcium administration

Pharmacotherapy

Volumn 31, Issue 10, 2011, Pages 1042-

  Roberts, Jennie L ^a   Kiser, Jennifer J ^a   Hindman, Jason T ^c   Meditz, Amie L ^b  

^a Division of Infectious Diseases   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

calcium; drug interaction; integrase; raltegravir; resistance

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ACICLOVIR; ARIPIPRAZOLE; ATAZANAVIR; CALCIUM CARBONATE; COLECALCIFEROL; EMTRICITABINE; ESOMEPRAZOLE; GABAPENTIN; LAMIVUDINE; LAMOTRIGINE; LOPINAVIR; LORAZEPAM; OLANZAPINE; PREDNISONE; PROTEINASE INHIBITOR; RALTEGRAVIR; RAMELTEON; RITONAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ZOLPIDEM;

ADULT; ARTICLE; BEDTIME DOSAGE; BLOOD SAMPLING; BRAIN VASCULITIS; CASE REPORT; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTRITIS; GASTROINTESTINAL DISEASE; HIV RAPID TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PATIENT COMPLIANCE; PRESCRIPTION;

EID: 84914115966     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1592/phco.31.10.1042     Document Type: Article

References (15)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. December 1, 2009. Available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed June 9, 2010.
2. Merck & Co. Isentress (raltegravir) product information. Whitehouse Station, NJ; January 2010.
3. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010;464:232-6.
4. Moss D, Murphy M, Siccardi M, Khoo S, Back D, Owen A. Influence of pH on transcellular permability of raltegravir: unraveling the interaction with antacids and food [abstract 635]. Presented at the 18th conference on retroviruses and opportunistic infection, Boston, MA, February 27-March 2, 2011.
5. Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. J Acquir Immune Defic Syndr 2005;40:573-80.
6. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008;83:293-9.
7. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009;53:2852-6.
8. Blum MR, Chittick GE, Begley JA, Zong J. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol 2007;47:751-9.
9. Ceccherini-Silberstein F, Van Baelen K, Armenia D, et al. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother 2010;54:3938-48.
10. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806.
11. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010;55:39-48.
12. Ramanathan S, Shen G, Hinkle J, Enejosa J, Kearney BP. Pharmacokinetic evaluation of drug interactions with ritonavirboosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents [abstract 69]. Presented at the 8th international workshop on clinical pharmacology of HIV therapy, Budapest, Hungary, April 16-18, 2007.
13. Song I, Patel A, Min S, et al. Evaluation of antacid and multivitamin (MVI) effects on S/GSK1349572 pharmacokinetics in healthy subjects [abstract AI-1305]. Presented at the 49th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 11-15, 2009.
14. Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother 2010;54:4999-5003.
15. Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009;48:489-92.